Using the ACC's health equity strategy, we aim to achieve a culture of equitable cardiovascular care and heart health for all. The ACC is paving the road to health equity through advocacy, education, ...

Since its inception in 2012, the ACC Geriatric Cardiology Section quickly gained momentum and now has over 1,000 members and well over 300 Fellows-in-Training (FITs), making it one of the larger ...

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

Learn and stay certified — all in one program: The CMP blends continuous learning with assessment, making it an efficient, effective way to grow your expertise while maintaining your credentials.

We are a young, vibrant section dedicated to adding value to Section members interested in Innovation across the cardiovascular spectrum. Our section is member-driven and focused on all aspects of ...

Findings from the PREVUE-VALVE study presented at TCT 2025 shed light on the prevalence of valvular heart disease (VHD) and its subtypes among older Americans, as well as the influence of age, sex, ...

The newest clinical guideline released by the ACC and the American Heart Association (AHA) provides new and updated recommendations for preventing and optimally managing atrial fibrillation (AFib).

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to new research published in JACC and simultaneously presented at AHA 2024. Among the highlights: ...

The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...

The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...

The U.S. Food and Drug Administration (FDA) has approved finerenone to treat patients with heart failure (HF) with LVEF ≥40%. The approval was based on results from the FINEARTS-HF trial, presented at ...